Literature DB >> 12193703

Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA.

Jaeho Jung1, Ae-Kyung Yi, Xin Zhang, Jongseon Choe, Li Li, Yong Sung Choi.   

Abstract

Innate immunity has recently gained renewed interest in its ability to regulate adaptive immunity. Among the innate immune signals, CpG DNA has revealed its potential as a vaccine adjuvant. However, the cellular mechanism for the effect of CpG DNA on the humoral immune response is not well understood. Here, we investigated the effects of CpG DNA on human B cell differentiation using highly purified B cell subsets: naive, germinal center (GC), and memory B cells. In the in vitro culture system that mimics the primary or secondary immune response in vivo, CpG DNA markedly augmented the proliferation and generation of plasma cells from naive and memory B cells. CpG DNA dramatically increased plasma cell generation from GC B cells. However, CpG DNA did not have effect on memory B cell generation from GC B cells. These results suggest that CpG DNA potentiates the B cell adaptive immune response by enhancing terminal differentiation, but does not affect the generation of memory B cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193703     DOI: 10.4049/jimmunol.169.5.2368

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors.

Authors:  Sean R Christensen; Mark J Shlomchik
Journal:  Semin Immunol       Date:  2007-02-02       Impact factor: 11.130

2.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2003

3.  In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.

Authors:  Archana Thakur; Oxana Norkina; Lawrence G Lum
Journal:  Cancer Immunol Immunother       Date:  2011-06-29       Impact factor: 6.968

Review 4.  CpG DNA as a vaccine adjuvant.

Authors:  Christian Bode; Gan Zhao; Folkert Steinhagen; Takeshi Kinjo; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

5.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells.

Authors:  Jason D Marshall; Edith M Hessel; Josh Gregorio; Christina Abbate; Priscilla Yee; Mabel Chu; Gary Van Nest; Robert L Coffman; Karen L Fearon
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

7.  Identification of two subpopulations of purified human blood B cells, CD27- CD23+ and CD27high CD80+, that strongly express cell surface Toll-like receptor 9 and secrete high levels of interleukin-6.

Authors:  Fabrice Cognasse; Hind Hamzeh-Cognasse; Sandrine Lafarge; Patricia Chavarin; Bruno Pozzetto; Yolande Richard; Olivier Garraud
Journal:  Immunology       Date:  2008-04-28       Impact factor: 7.397

8.  Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine.

Authors:  Yichuan Wang; Shelley A Blozis; Michael Lederman; Arthur Krieg; Alan Landay; Christopher J Miller
Journal:  Clin Vaccine Immunol       Date:  2009-02-18

Review 9.  Antiinfective applications of toll-like receptor 9 agonists.

Authors:  Arthur M Krieg
Journal:  Proc Am Thorac Soc       Date:  2007-07

10.  Genome-wide scan identifies a copy number variable region at 3p21.1 that influences the TLR9 expression levels in IgA nephropathy patients.

Authors:  Fabio Sallustio; Sharon N Cox; Grazia Serino; Claudia Curci; Francesco Pesce; Giuseppe De Palma; Aikaterini Papagianni; Dimitrios Kirmizis; Mario Falchi; Francesco P Schena
Journal:  Eur J Hum Genet       Date:  2014-10-08       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.